MEMS  

 
  MEMS  
About MEMS   |   Council   |   Members Centre   |   Membership   |   Contact Us   |   Home
  Member Login     username:     password:           Forgot your password?
  Home » Announcements & Updates » 
President’s Message
The Endocrine Directory
Calendar of Events
Announcements & Updates
Breaking News & Reports
CME
CPG
In the Press
Disease Areas
Healthy Lifestyle
Publications
Research Programs
Awards
Photo & Video Gallery
Useful Links
Disease Management
Home
 
arrow Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy
5-03-2010
Type 2 diabetes mellitus affects approximately 24 million people in the United States, is the leading cause of kidney failure and blindness, and is associated with a doubling to quadrupling of the risk of death from cardiovascular causes. Furthermore, the prevalence of type 2 diabetes is expected to increase because of the obesity epidemic.
»Read more...
 


arrow Glycaemic Control: How Low Should We Go?
15-02-2010
Since the publication of the UK Prospective Diabetes Study (UKPDS) it has become widely accepted that the lower the A1c level the better is the outcome for patients with type 2 diabetes especially in terms of reducing microvascular complications. This contention is also supported by the Diabetes Control and Complications Trial (DCCT) which involved patients with type 1 diabetes. Based on the DCCT study the American Diabetes Association (ADA) set the target of 7.0 % for A1c levels while the rest of the world settle for 6.5 % instead.
»Read more...
 


arrow FDA Communication about an Ongoing Safety Review of Sibutramine
28-01-2010
The U.S. Food and Drug Administration (FDA) has reviewed additional data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine, marketed as the weight loss medication Meridia.
»Read more...
 


arrow New UK data support ACCORD findings, emphasize need for individualization of blood glucose control
28-01-2010
A new retrospective cohort study in patients with type 2 diabetes has found that the lowest and highest glycated hemoglobin A1c (HbA1c) levels were associated with increased all-cause mortality and cardiac events [1]. This U-shaped association showed that the lowest death and lowest event rates were seen at an HbA1c level of 7.5%, say Dr Craig J Currie (Cardiff University, Wales) and colleagues in their paper published online January 27, 2010 in the Lancet.
»Read more...
 


arrow MEMS extend our deepest condolences to Prof. Dato' Khalid Kadir and his family
10-01-2010
Malaysian Endocrine & Metabolic Society would like to extend our deepest condolences to Prof. Dato' Khalid Kadir and his family on the passing away of his beloved mother, the late Tun Fatimah Hashim. We request our Muslim members to recite Al Fatehah.

Yours sincerely,

Malaysian Endocrine & Metabolic Society
»Read more...
 


arrow New joint statement streamlines definition of Metabolic Syndrome
12-12-2009
A new joint statement from a number of professional organizations has identified specific criteria for the clinical diagnosis of the metabolic syndrome, tightening up the definition, which previously differed from one organization to the next.
»Read more...
 


 
   
 



 
 
| | | |
© Copyright Malaysian Endocrine & Metabolic Society (MEMS)   2009 - 2016    All rights reserved.
designed & maintained: mobition